|
Volumn 17, Issue 4 Suppl 2, 2011, Pages
|
An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALLOPURINOL;
ANTIGOUT AGENT;
FEBUXOSTAT;
THIAZOLE DERIVATIVE;
URIC ACID;
XANTHINE OXIDASE;
ARTICLE;
BLOOD;
CLINICAL TRIAL;
COMPARATIVE STUDY;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE RESPONSE;
DOUBLE BLIND PROCEDURE;
DRUG ANTAGONISM;
FEMALE;
FOLLOW UP;
GOUT;
HUMAN;
HYPERURICEMIA;
JAPAN;
MALE;
MIDDLE AGED;
MULTICENTER STUDY;
ORAL DRUG ADMINISTRATION;
PHASE 2 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
TIME;
TREATMENT OUTCOME;
ADMINISTRATION, ORAL;
ALLOPURINOL;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DOUBLE-BLIND METHOD;
FEMALE;
FOLLOW-UP STUDIES;
GOUT;
GOUT SUPPRESSANTS;
HUMANS;
HYPERURICEMIA;
JAPAN;
MALE;
MIDDLE AGED;
THIAZOLES;
TIME FACTORS;
TREATMENT OUTCOME;
URIC ACID;
XANTHINE OXIDASE;
|
EID: 84863907278
PISSN: None
EISSN: 15367355
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (33)
|
References (0)
|